People

Finnish particle engineering company Nanoform has named former Hovione executive Miguel Calado as Vice Chairman of the Board. In addition to having served as CFO and VP of Finance of Hovione, Calado has also been… Read more . . .

Synspira Therapeutics, which is developing an inhaled therapy for cystic fibrosis, has announced the appointment of Robert Gallotto as President and CEO. Gallotto was most recently President and co-founder of Alcresta Therapeutics. He previously co-founded… Read more . . .

Swedish DPI company Iconovo has announced the appointment of Roger Lassing as Vice President Business Development. Lassing, who was most recently Senior Manager of Global Business Development at LEO Pharma, has previously held executive positions… Read more . . .

Acorda Therapeutics has announced the appointment of Peter S. Carbone as Senior VP, Quality. Carbone was most recently VP of Quality Solids Americas & Special Technologies at Novartis and previously held executive positions at Amgen… Read more . . .

Device company Nemera has announced the promotion of the leader of its Innovation Center, Dimitri Grasswill, to VP of Innovation. Grasswill has directed the Innovation Center, located in La Verpillière, France, since 2013. In a… Read more . . .

Dance Biopharm, which is developing an insulin soft mist inhaler, has named Melissa Rhodes as Chief Development Officer and Michael Kaseta as its new Chief Financial Officer. The company said that former CFO Don Huffman… Read more . . .

Inhaler filling experts Harro Höfliger have announced a number of management changes after the retirement of its founder, Harro Höfliger, who has been succeeded by his son, Markus Höfliger as Chairman of the Supervisory Board.… Read more . . .

Nanoform, which recently announced construction of a new GMP manufacturing facility in Helsinki, has announced the appointment of Niklas Sandler as Chief Technology Officer. Sandler was most recently Vice Rector responsible for Research Affairs and… Read more . . .

Verona Pharma, which is developing an inhaled PDE3/PDE4 inhibitor, has named Kathleen Rickard as Chief Medical Officer and Tara Rheault as VP of Research and Development Operations and Global Project Management. Rickard has previously served… Read more . . .